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The endurance shuttle walk test (ESWT) is used to evaluate exercise tolerance in patients
with chronic obstructive pulmonary disease (COPD). The recommended pre-intervention
tolerated duration (Tlim) is between 3–8 minutes for optimal interpretation of treatment
effects. However, this window may be exceeded and factors determining ESWT Tlim are
not completely understood. Therefore, we aimed to determine whether pulmonary function,
physical and incremental shuttle walk test (ISWT) performance measures are associated
with ESWT Tlim in COPD patients.
Methods
Assessment data from patients eligible for pulmonary rehabilitation was retrospectively ana-
lyzed. Inclusion criteria were: diagnosis of COPD and complete data availability regarding
ESWT and ISWT. Patients performed an ESWT at 85% of ISWT speed and were divided
into three groups (ESWT Tlim: <3 minutes, 3–8 minutes, >8 minutes). Subject characteris-
tics, severity of complaints, pulmonary function, physical capacity and activity, exercise tol-
erance and quadriceps muscle strength were evaluated.
Results
245 COPD patients (FEV1 38 (29–52)% predicted) were included. Median ESWT Tlim was
6.0 (3.7–10.3) minutes, 41 (17%) patients walked <3 minutes and 80 (33%) patients walked
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>8 minutes. Body mass index, maximal oxygen consumption, Tlim on constant work rate
cycle test, physical activity level, maximal ISWT speed, dyspnoea Borg score at rest and
increase of leg fatigue Borg score during ISWT independently predicted Tlim in multivariate
regression analysis (R2 = 0.297, p<0.001).
Conclusion
This study reported a large variability in ESWT Tlim in COPD patients. Secondly, these
results demonstrated that next to maximal ISWT speed, other ISWT performance measures
as well as clinical measures of pulmonary function, physical capacity and physical activity
were independent determinants of ESWT Tlim. Nevertheless, as these determinants only
explained ~30% of the variability, future studies are needed to establish whether additional
factors can be used to better adjust individual ESWT pace in order to reduce ESWT Tlim
variability.
Introduction
The endurance shuttle walk test (ESWT) is commonly used to evaluate effects of interventions
on exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) [1, 2] in
both research and clinical settings [3]. This accessible and low-cost field walking test is per-
formed at an imposed constant pace and is therefore better controlled than other field walking
tests, like the 6- and 12-minute walking tests [4–6]. Furthermore, the tolerated duration (Tlim)
of the ESWT is considered to be highly responsive to interventions, especially in comparison
to maximal walking tests [1, 7] and the change in ESWT Tlim has been associated with change
in exercise capacity and quality of life [8, 9].
However, the potential effect size of interventions on Tlim of constant load tests is strongly
determined by the load on which the test is performed [10]. Since Tlim has a negative hyper-
bolical relation with the relative load of the test, testing at higher relative loads will yield less
potential improvement on Tlim [10–12]. Accordingly, ESWT load, i.e. pace, is set at a fixed
percentage (usually 85%) of the maximum walking pace, pre-determined by an incremental
shuttle walk test (ISWT) [6]. Despite this fixed pace, considerable variability in ESWT Tlim
was recently observed in patients with COPD (ESWT Tlim = 353 seconds, 95% CI [299–407]
[13]). Because effects sizes of interventions on ESWT Tlim depend on pre-intervention ESWT
Tlim, a large variability in pre-intervention ESWT Tlim complicates statistical analysis of
intervention efficacy and increases the number of participants required in clinical studies [12,
14]. Accordingly, a pre-intervention Tlim between 3 and 8 minutes has been recommended
for constant load exercise tests, like the ESWT [15].
It is currently not completely understood why Tlim of some patients falls outside the rec-
ommended timeframe of 3–8 minutes. However, we do know that causes of exercise intoler-
ance are multifactorial and heterogenous in patients with COPD [16]. Next to the severity of
pulmonary dysfunction, extrapulmonary features, like muscle weakness and psychological sta-
tus are known to determine tolerance to exercise [10, 16, 17]. Furthermore, the variability of
endurance time on a constant work rate cycle exercise test (CWRT) with equal relative loads
for all COPD patients was only partly explained by peak exercise capacity and maximal quadri-
ceps strength [18], suggesting that variability of endurance time is determined by additional
clinical variables. Whether these factors influence ESWT Tlim as well has not yet been
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database and can be accessed at the following DOI:
https://doi.org/10.17026/dans-xd6-2fw9.
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determined. Lastly, procedural factors can also play a role in ESWT Tlim variability. For exam-
ple, over- and underestimation of the maximal speed obtained from ISWT can lead to ESWT
performance at an intensity not truly representing 85% of the peak capacity. Hence, a perfor-
mance of the ISWT in accordance with the European Respiratory Society/American Thoracic
Society Technical Standards is important [19], as well as maximal effort of the patient.
Collectively, considering that despite protocolized execution of ISWT and ESWT substan-
tial heterogeneity is observed in ESWT Tlim in patients with COPD, hampering clinical evalu-
ation of interventions, there is a need to better understand determinants of ESWT Tlim
variation. Therefore, our primary aim was to determine whether pulmonary function, physical
and ISWT performance variables are associated with ESWT Tlim in patients with COPD. A
priori, we hypothesized that parameters of pulmonary function and physical performance are
independent determinants of ESWT Tlim and can partly explain the high variability of ESWT
Tlim in patients with COPD.
Materials and methods
Retrospective analyses were performed on an anonymized dataset from 306 patients that
attended a comprehensive pulmonary rehabilitation (PR) program in Dekkerswald–Radbou-
dumc (Nijmegen, The Netherlands) between September 2016 and December 2019. The data
was collected during baseline assessment as part of standard care of the PR program. Inclusion
criteria for the analyses were a primary diagnosis of COPD according to the Global Initiative
for Chronic Obstructive Lung Disease criteria [20] and complete data availability regarding
ISWT speed and ESWT speed and time. These criteria were met by 245 patient. A flowchart of
in- and exclusion of patients is depicted in Fig 1.
This study was in accordance to the principles of the Declaration of Helsinki. The local ethi-
cal board Arnhem/Nijmegen, The Netherlands, informed the authors that the Medical
Research Involving Human Subject Act (WMO) did not apply to this retrospective study
(2020–6621).
Fig 1. Flowchart of in- and exclusion of patients for analysis. Definitions of abbreviations: COPD = chronic
obstructive pulmonary disease, CPET = cardiopulmonary exercise test, CWRT = constant work rate test,
HR = heartrate, ISWT = incremental shuttle walk test, ESWT = endurance shuttle walk test.
https://doi.org/10.1371/journal.pone.0249786.g001
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Measurements
Subject characteristics and severity of complaints as age, gender, weight, body mass index
(BMI), Charlson Comorbidity Index [21], fat-free mass index, modified Medical Research
Council (mMRC) [22], COPD Assessment Test [23], Hospital Anxiety and Depression Scale
[24] and Checklist Individual Strength Fatigue [25] were systemically assessed.
Pulmonary function tests. Post-bronchodilator pulmonary function tests including spi-
rometry (forced expiratory volume in one second, FEV1; Tiffeneau index, FEV1/vital capacity),
static lung volumes (residual volume, RV; functional residual capacity, FRC; total lung capac-
ity, TLC) and diffusion capacity for carbon monoxide (DLCO) by single-breath method (Mas-
terScreen PFT/Body; Jaeger, Würzburg, Germany) were executed according to the European
Respiratory Society Recommendations [26] and related to predicted normal values [27, 28].
Physical performance tests. The ISWT required the patients to walk around two markers
set nine meters apart (10 meters course) at a speed which increases every minute indicated by a
pre-recorded audio signal. The patients were instructed to walk for as long as possible [29]. The
ESWT was performed at 85% of the maximal ISWT speed and used the same course and audi-
tory signal method. In contrast to the ISWT, the patients were required to walk at a constant
speed throughout the test for as long as possible. The ESWT had a maximum test duration of 20
minutes for practical reasons [6]. Both tests were performed according to standardized proto-
cols [6, 29] with on average one week in-between. The following ISWT and ESWT parameters
were recorded: Tlim, walking distance, speed, resting and maximal values of transcutaneous
peripheral oxygen saturation (SpO2), heartrate (HR) and Borg scores (dyspnoea and leg fatigue).
Furthermore, the ISWT distance in meters was calculated as percentage of predicted [30].
Patients with beta blockers (n = 30) or missing information regarding beta blockers (n = 31)
were excluded from analyses on HR responses to exercise during both shuttle walk tests (Fig 1).
A symptom-limited ramp maximal cardiopulmonary exercise test (CPET) was performed
on an electromagnetically braked cycle ergometer (Ergoselect, Ergoline, Bitz, Germany)
according to the recommended guidelines [31] to determine the maximal workload (Wmax)
and oxygen uptake (VO2max). Furthermore, the maximal HR was recorded in order to deter-
mine the maximal HR during the ISWT relative to the maximal HR during the CPET
(HRmaxISWT/HRmaxCPET). The CWRT was performed at 65% of Wmax on the same cycle
ergometer as the CPET. Patients cycled until symptom limitation or until pedalling rate
decreased under 60 rotations per minute, with a maximum of 20 minutes. Only data of
patients that performed CPET with maximal effort, as based on the European Respiratory
Society and American Thoracic Society/ American College of Chest Physicians statements on
CPET, were included in analysis of CPET and CWRT variables (n = 204) [31, 32] (Fig 1).
Isometric quadriceps strength (maximal voluntary contraction) was assessed with a com-
puterized dynamometer (Biodex System 4 Pro, Biodex Medical Systems, Inc., New York,
USA). Participants performed three maximal unilateral isometric knee extensions for five sec-
onds at a knee angle of 60˚, interspersed with 15 seconds of rest. The maximal voluntary con-
traction was defined as the highest peak torque (Nm) [33] and was both expressed as absolute
value as well as related to predicted normal values [34].
Physical activity was measured using the Dynaport MoveMonitor (McRoberts BV, The
Hague, The Netherlands) for a duration of seven (with a minimum of at least five) consecutive
days and defined as steps per day and average physical activity level (PAL) [35, 36].
Statistical analysis
Statistical analyses were performed using SPSS statistical software program (IBM, New York,
USA), version 25.0. Descriptive data were presented as mean ± SD, median (interquartile
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range 25–75%) or number of patients (percentage), as appropriate. Based on the ESWT Tlim,
the subjects were divided into three groups (group 1:<3 minutes, group 2: 3–8 minutes, group
3:>8 minutes). These cut-off points were chosen to reflect the desirable ESWT duration of 3
to 8 minutes [15]. Accordingly, in the results section we focussed on differences in groups 1
and 3 compared to group 2.
Between-groups comparisons for continuous variables were tested by one-way analysis of
variance (ANOVA) or Kruskal-Wallis test, as appropriate. Categorical variables were tested
with a Chi-square test. When a statistically significant difference was obtained, a pairwise post-
hoc test was performed and Bonferroni post-hoc testing was applied to correct for multiple
comparisons. A p-value of<0.05 was considered significant.
Univariate and multivariate linear regression models were used to evaluate the association
of pulmonary function, physical and ISWT performance variables with the ESWT Tlim. Uni-
variate linear regression models were built using the ENTER method. Explanatory variables
with a p-value <0.20 and not strongly correlated (r<0.8) with another variable of interest
were used to build a multivariate linear regression model, using the backward method. Vari-
ables with a p-value<0.05 in the multivariate linear regression model were considered as inde-
pendent predictors of ESWT Tlim.
Results
The included patients had a mean age of 61.4±7.8 years, a mean BMI of 25.8±5.7 kg/m2, a
median FEV1 of 38 (29–52)% predicted and 47% were male (Table 1). The median ESWT Tlim
was 6.0 (3.7–10.3) minutes. A total of 41 (17%) patients walked<3 minutes (group 1), 124
(50%) patients walked between 3–8 minutes (group 2) and 80 (33%) patients walked>8 min-
utes (group 3). Furthermore, 42 (17%) patients reached the maximum test duration of 20 min-
utes. The distribution of patients according to the ESWT Tlim is depicted per minute in Fig 2.
Subgroup characteristics
Gender, BMI, fat free mass index and Charlson Comorbidity Index were similar between
groups. Patients in group 3 were younger (59.4±8.6) than patients in group 2 (62.4±7.2,
p = 0.021). The severity of dyspnea sensation, as reflected by the mMRC score, was lower in
patients from group 3 (median 2(1–3) and mean 1.8±1.2) than group 2 (median 2(1–3) and
mean 2.2±1.2, p = 0.006). There were no differences in severity of complaints, COPD Assess-
ment Test, Hospital Anxiety and Depression Scale and Checklist Individual Strength Fatigue
scores, between the groups (Table 1).
Pulmonary function and physical performance parameters. Pulmonary function of
patients in group 2 were similar to patients in group 1 and 3, except for a lower FEV1 (L) in
group 1 than group 2 (p<0.001). Measures of physical performance, like maximal exercise
capacity, muscle strength and physical activity were comparable between patient in group 1
and 2. Patients in group 3 had a better physical capacity (Wmax and VO2max) and were more
physically active (steps/day and average PAL) in comparison to group 2 (all p-values <0.001)
(Table 1).
ISWT performance parameters. The median ISWT distance of all patients was 280 (200–
390) meters. Group 1, 2 and 3 walked 205 (173–328) meters, 285 (200–380) meters and 320
(213–438) meters, respectively. Patients in group 1 desaturated more during the ISWT than
group 2 (all p-values <0.001). Furthermore, these patients had a higher rest and maximal dys-
pnoea Borg score in comparison to group 2 (p<0.001, p = 0.011, respectively). Although the
HR before and at the end of the ISWT was comparable between the three groups, the maximal
HR during ISWT in ratio to the maximal HR reached during CPET (HRmaxISWT/
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HRmaxCPET) was lower in patients from group 3 than in patients from group 2 (p = 0.002).
Other ISWT performance parameters were not significantly different for group 1 and 3 in
comparison to group 2 (Table 2).
Table 1. Subject characteristics, severity of complaints and parameters of pulmonary function and physical performance of the whole group and the three sub-
groups based on tolerated duration during the ESWT.
All patients with COPD (n = 245) Group 1 (n = 41) Group 2 (n = 124) Group 3 (n = 80)
Variables Tlim <3 min Tlim = 3–8 min Tlim >8 min p-value
Gender (male, %) 114 (47) 17 (42) 61 (49) 36 (45) 0.653
Age (years) 61.4 ± 7.8 61.9 ± 7.1 62.4 ± 7.2 59.4 ± 8.6 0.021†
BMI (kg/m2) 26 ± 6 26 ± 7 26 ± 5 25 ± 6 0.195
CCI a 1 (1–2) 1 (1–3) 1 (1–2) 1 (1–2) 0.853
FFMI b 16.9 ± 2.5 16.8 ± 3.1 17.2 ± 2.3 16.6 ± 2.5 0.296
Severity of complaints
mMRC score c 2 (1–3) 2 (2–3) 2 (1–3) 2 (1–3) 0.006#,†
CAT score d 17.2 ± 7.0 17.3 ± 6.5 16.9 ± 7.4 17.7 ± 6.7 0.784
HADS anxiety score e 8.5 ± 4.2 8.7 ± 5.0 8.3 ± 4.0 8.6 ± 4.1 0.852
HADS depression score e 8.6 ± 3.8 8.6 ± 4.3 8.2 ± 3.7 9.1 ± 3.6 0.349
CIS fatigue score f 48 (43–53) 48 (42–52) 48 (44–53) 49 (44–54) 0.836
Pulmonary function parameters
FEV1 (L)
g 1.1 (0.8–1.5) 0.9 (0.7–1.2) 1.0 (0.8–1.5) 1.2 (0.9–1.8) <0.001� ,#
FEV1 (% predicted)
g 38 (29–52) 31 (27–42) 37 (29–49) 44 (33–56) 0.001#
Tiffeneau index (%) g 34.5 (28.0–45.5) 31.7 (26.7–38.6) 33.5 (26.9–43.7) 37.8 (30.8–50.2) 0.005#
FRC (% predicted) h 163 ± 38 169 ± 37 165 ± 38 156 ± 39 0.158
RV (% predicted) i 191 ± 53 201 ± 52 191 ± 54 186 ± 53 0.394
TLC (% predicted) i 123 ± 19 125 ± 20 124 ± 19 122 ± 18 0.591
FRC/TLC (%) h 70 ± 9 72 ± 9 70 ± 9 67 ± 10 0.009#
RV/TLC (%) i 56 ± 10 60 ± 9 56 ± 10 54 ± 10 0.026#
DLCO (mL/mmHg/min)
j 3.6 ± 1.6 3.0 ± 1.4 3.6 ± 1.5 3.9 ± 1.8 0.011#
DLCO (% predicted)
j 42 ± 16 36 ± 15 42 ± 15 45 ± 18 0.021#
Physical performance parameters
Wmax (Watts) k 70 ± 34 53 ± 25 68 ± 34 82 ± 34 <0.001#,†
VO2Max (ml/min/kg)
l 13.8 (11.8–16.8) 12.5 (10.7–13.7) 13.4 (11.8–16.1) 16.1 (13.6–18.3) <0.001#,†
VO2Max (% predicted)
l 58 (48–67) 52 (45–63) 57 (47–66) 61 (50–74) 0.008#
CWRT time (s) m 300 (187–495) 224 (165–290) 294 (180–433) 327 (218–600) 0.028#
MVC (Nm) n 117 ± 38 113 ± 30 120 ± 42 114 ± 37 0.414
MVC (% predicted) n 63 ± 15 64 ± 14 64 ± 16 62 ± 13 0.445
Physical activity (steps/day) o 3480 (2386–5168) 2651 (1517–3923) 3228 (2388–4752) 4732 (2934–6097) <0.001#,†
Physical activity (average PAL) p 1.34 (1.29–1.42) 1.30 (1.26–1.35) 1.34 (1.29–1.41) 1.38 (1.31–1.48) <0.001#,†
Data is presented as mean ± SD, median (IQR 25–75%) or number of patients (percentage), as appropriate.
� indicates a significant difference after Bonferroni post-hoc correction between group 1 and group 2
# indicates a significant difference after Bonferroni post-hoc correction between group 1 and group 3
† indicates a significant difference after Bonferroni post-hoc correction between group 2 and group 3. Alphabetic characters in superscript indicate a sample size deviant
from n = 245 (group 1: 41, group 2: 124, group 3: 80) with the following: a. n = 226 (37, 116, 73), b. n = 209 (37, 101, 71), c. n = 222 (39, 112, 71), d. n = 214 (37, 106, 71),
e. n = 221 (39, 111, 71), f. n = 223 (39, 112, 72), g. n = 240 (41, 121, 78), h. n = 235 (39, 120, 76), i. n = 236 (39, 121, 76), j. n = 228 (39, 114, 75), k. n = 203 (33, 104, 66), l.
n = 194 (33, 97, 64), m. n = 154 (21, 78, 55), n. n = 226 (40, 112, 74), o. n = 242 (40, 123, 79), p. n = 241 (40, 122, 79). Definitions of abbreviations: BMI = Body Mass
Index, CAT = COPD Assessment Test, CCI = Charlson Comorbidity Index, CIS = Checklist Individual Strength, CWRT = constant work rate cycle test, DLCO = single-
breath carbon monoxide diffusion capacity, FEV1 = forced expiratory volume in 1 second, FFMI = fat free mass index, FRC = functional residual capacity,
HADS = Hospital Anxiety and Depression Scale, mMRC = modified Medical Research Council, MVC = maximal voluntary contraction, PAL = physical activity level,
TLC = total lung capacity, Tlim = tolerated duration, RV = residual volume, VO2max = maximal oxygen uptake, Wmax = maximal workload.
https://doi.org/10.1371/journal.pone.0249786.t001
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ESWT performance parameters. Patients with an ESWT Tlim>8 minutes had a higher
maximal oxygen saturation and higher resting and maximal dyspnoea Borg score during the
ESWT than patients from group 2 (all p-values <0.001). Besides speed and time, other ESWT
performance parameters of patients from group 1 and 3 were comparable to group 2 (S1
Table).
Predictors of ESWT time. Univariate linear regression models that were used to explain
ESWT Tlim variability are documented in S2 and S3 Tables. Age, BMI, mMRC and several
variables of pulmonary function (FEV1, Tiffeneau index, FRC, FRC/TLC, RV/TLC and
DLCO), physical performance (Wmax, VO2max, CWRT time, steps/day and average PAL) and
ISWT performance (distance, speed, SpO2, HRmaxISWT/HRmaxCPET and Borg scores for dys-
pnoea and leg fatigue) were significant explanatory variables of ESWT Tlim in univariate
analyses.
In a multivariate linear regression model, BMI, VO2max, CWRT time, average PAL, ISWT
speed, dyspnoea Borg score at rest and increase of leg fatigue Borg score during ISWT were
independent predictors of ESWT Tlim (S4 Table). This model explained ~30% of the variabil-
ity in ESWT Tlim (R2 = 0.297, p<0.001).
Discussion
The current study confirmed that patients with COPD display a large variability in ESWT
Tlim, even though ESWT was performed at a fixed percentage of pre-determined maximal
walking speed. To our knowledge, this is the first study that determined possible predictors of
ESWT Tlim in patients with COPD. We found that BMI, VO2max, CWRT time, average PAL,
ISWT speed, dyspnoea Borg score at rest and increase of leg fatigue Borg score during ISWT
are independent predictors of ESWT Tlim. However, collectively these determinants can only
explain ~30% of ESWT Tlim variability.
ESWT Tlim highly variable
A large interindividual variability in ESWT Tlim was illustrated by the notion that half of the
patients with COPD performed the ESWT outside the desired duration of 3–8 minutes. Fur-
thermore, a required termination of the test was needed in 17% of the patients as they reached
the maximum test duration of 20 minutes, but probably could have walked even longer. This
Fig 2. The distribution of patients according to the ESWT Tlim per minute.
https://doi.org/10.1371/journal.pone.0249786.g002
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large interindividual variability is in accordance with a recent study of Maltais et al., who
investigated the responsiveness of the ESWT to bronchodilation [13]. In their analysis the
authors were urged to exclude patients that had a baseline ESWT Tlim of more than 15 min-
utes to allow measurable room for improvement on a post-intervention ESWT. So, high inter-
individual variability in ESWT Tlim requires a larger number of participants in clinical studies
to detect an effect of interventions. The interpretation of intervention efficacy is even more
complicated as the potential effect size (i.e. post–pre intervention) of ESWT Tlim depends on
the pre-intervention ESWT Tlim due to the hyperbolic nature of the load-duration relation-
ship [12]. Therefore, in a population with a high interindividual variability in ESWT Tlim,
individual effects of interventions are difficult to compare [12, 14, 15]. The best solution to
reduce this variability is to determine the load-duration relationship in every individual. How-
ever, this is clinically impractical because it requires the completion of several ESWT tests at
various intensities. Another possibility is to perform a second ESWT at an adjusted pace in
patients with an ESWT Tlim<3 or >8 minutes. However, the size of the adjustment in pace
has not been determined yet and a second ESWT is not always possible due to practical reasons
like time constraints. Therefore, it is important to search for other possibilities to reduce the
variability in ESWT Tlim. One option would be to better predict the ESWT Tlim prior to its
performance in order to individually adjust the ESWT pace with clinical available measures.
Therefore, this study further investigated correlates of ESWT Tlim variability.
Table 2. ISWT performance parameters of the whole group and the three subgroups based on tolerated duration during the ESWT.
All patients with COPD (n = 245) Group 1 (n = 41) Group 2 (n = 124) Group 3 (n = 80)
Variables Tlim <3 min Tlim = 3–8 min Tlim >8 min p-value
Distance (m) a 280 (200–390) 205 (173–328) 285 (200–380) 320 (213–438) 0.004#
Distance (% predicted) b 45 (30–58) 33 (25–49) 47 (29–58) 47 (34–64) 0.015#
Speed (km/h) 4.8 (4.2–5.4) 4.2 (3.6–5.1) 4.8 (4.2–5.4) 4.8 (4.2–6.0) 0.029#
SpO2 rest (%) 96 (94–97) 95 (93–96) 96 (94–97) 96 (94–98) 0.146
SpO2 at max (%) 89 (85–94) 85 (82–91) 90 (85–94) 90 (87–94) 0.001
� .#
SpO2 delta (max-rest, %) -7 (-11- -2) -9 (-13- -6) -6 (-11- -2) -5 (-9- -1) 0.002
� .#
HR rest (bpm) c 84 ± 12 86 ± 12 84 ± 13 83 ± 10 0.632
HR at max (bpm) c 113 ± 19 114 ± 16 114 ± 21 110 ± 17 0.507
HRmaxISWT/HRmaxCPET
d 92 ± 14 97 ± 10 94 ± 17 87 ± 11 0.002#,†
HR delta (max-rest, bpm) c 29 ± 15 27 ± 11 30 ± 17 27 ± 15 0.379
Borg score dyspnoea rest 2 (1–3) 2 (1–3) 2 (1–3) 1 (0–2) 0.058
Borg score dyspnoea max 5 (4–7) 7 (5–7) 5 (4–7) 5 (3–7) <0.001� .#
Borg score dyspnoea delta 3 (2–5) 5 (3–6) 3 (2–5) 3 (2–5) 0.011� .#
Borg score fatigue rest 2 (1–3) 3 (1–5) 2 (1–3) 2 (1–4) 0.221
Borg score leg fatigue max 5 (3–7) 5 (3–7) 5 (3–7) 4 (3–6) 0.238
Borg score leg fatigue delta 2 (1–4) 3 (1–5) 2 (1–4) 2 (0–3) 0.065
Data is presented as mean ± SD or median (IQR 25–75%), as appropriate.
� indicates a significant difference after Bonferroni post-hoc correction between group 1 and group 2
# indicates a significant difference after Bonferroni post-hoc correction between group 1 and group 3
† indicates a significant difference after Bonferroni post-hoc correction between group 2 and group 3. Alphabetic characters in superscript indicate a sample size deviant
from n = 245 (group 1: 41, group 2: 124, group 3: 80) with the following: a. n = 242 (40, 122, 80), b. n = 243 (40, 123, 80), c. n = 184 (27, 91, 66), d. n = 167 (25, 80, 62).
Definitions of abbreviations: HR = heartrate, HRmaxISWT/HRmaxCPET = maximal HR of the incremental shuttle walk test relative to the maximal HR during the
cardiopulmonary exercise test, SpO2 = peripheral capillary oxygen saturation, Tlim = tolerated duration.
https://doi.org/10.1371/journal.pone.0249786.t002
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Pulmonary function and physical performance parameters
Patients performing the ESWT longer than 8 minutes had a higher physical capacity and activ-
ity in comparison to group 2. In addition, exercise tolerance obtained by CWRT was also posi-
tively related to the ESWT Tlim. On the other hand, patients that could not sustain the ESWT
for at least 3 minutes, were characterized by a lower FEV1 (L) than patients in group 2 and sev-
eral pulmonary function measures were negatively associated with ESWT Tlim. Pulmonary
dysfunction is a well-known contributor to exercise intolerance in patients with COPD [10,
11]. In short, ventilatory capacity is limited by airflow obstruction and hyperinflation, which
may even exacerbate during exercise. On the other hand, ventilatory demand in patients with
COPD may be increased as a result of abnormal pulmonary gas exchange, increased work of
the respiratory muscles and early lactate production in the peripheral muscles [16, 37–40].
This leads to increased sensations of dyspnoea during exercise and explains why the severity of
pulmonary dysfunction is related to the ability to sustain a certain exercise load [37, 38]. How-
ever, it should be stressed that the load of the ESWT is normalized for maximal exercise capac-
ity, as ESWT pace is individually set at 85% of maximal ISWT pace. Despite this
normalization, pulmonary function, physical capacity and physical activity are still related to
the time patients can sustain this individually assessed pace. This suggests that the load-dura-
tion relationship is affected by these measures. The load-duration relation is described by two
parameters; the critical load and the curvature constant [10–12]. Neder et al. previously
reported that both parameters are reduced in patients with COPD in comparison to healthy
controls [11]. The results of the current study suggest that even within the COPD population,
critical load and the curvature constant might be influenced by pulmonary function, physical
capacity and physical activity.
Thus, the current findings suggest that, in addition to maximal ISWT pace, measures of
pulmonary function, physical capacity and physical activity, if clinically available, might be
helpful to more adequately set ESWT pace. It appears that patients with more severe airway
obstruction should be set at paces slower than 85% of maximal pace and patients with higher
physical capacity and activity levels at paces faster than 85% of maximal pace. However, exact
cut-off values and sizes of adjustment should be explored in future studies.
ISWT performance parameters
Because ESWT pace is based on maximal ISWT speed, it is essential that the ISWT is per-
formed with maximal effort and using a standardized operating procedure. Therefore, we
investigated performance measures obtained during ISWT. In contrast to healthy individuals,
the exercise capacity of most patients with COPD is not limited by cardiac output [37]. So
maximum HR during ISWT cannot be used to establish maximal effort in patient with COPD.
Accordingly, we examined ISWT HR in ratio to the maximum HR obtained during CPET, i.e.
HRmaxISWT/HRmaxCPET. We found that this ratio was significantly lower in patients that dis-
played an ESWT Tlim >8 minutes (group 3). Furthermore, the ratio was negatively associated
with ESWT Tlim. This indicates that some patients with an ESWT time >8 minutes might
have performed sub-maximally on their ISWT. A longer ESWT Tlim was also associated with
a reduced increase of perceived leg fatigue during ISWT. Although this is a subjective measure,
it is in line with a sub-maximal effort during the ISWT. A more objective indication of maxi-
mal effort can be provided by additional physiological measures like minute ventilation, oxy-
gen consumption and/or blood lactate values [31], but these would make the ISWT less
accessible and more expensive. Our data suggest that if maximal attained HR during CPET is
available it can be used together with simple non-invasive measurement of HR during ISWT
to provide an estimation of ISWT effort.
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Additionally, patients with a shorter ESWT Tlim desaturated more during the ISWT than
patients with a longer ESWT Tlim, which was also reported during the ESWT. This might sug-
gest that patients who desaturate more during the ISWT should perform the ESWT at a lower
relative load than 85%.
Predicting ESWT
Because our data showed that several clinically obtained measures significantly correlated with
ESWT Tlim, we further investigated if a model could be built to predict ESWT Tlim. Based on
a multivariate linear regression model, BMI, VO2max, CWRT time, physical activity, ISWT
speed, dyspnoea Borg score at rest and delta leg fatigue Borg score during ISWT were identi-
fied as independent predictors of ESWT Tlim. Although each of these parameters significantly
contributes to ESWT Tlim variability, the total explained variance is only ~30%. Therefore, it
is important to evaluate additional factors that might be associated with ESWT Tlim. For
example, dynamic hyperinflation and reduced leg muscle endurance are known to frequently
occur in patients with COPD and affect exercise tolerance independent of the severity of pul-
monary dysfunction [2, 39, 41–43]. Further research is necessary to assess if these or other fac-
tors could improve the accuracy of predicting ESWT Tlim. Eventually, a proper prediction
model with clinical available measures might help clinicians to identify patients that are
expected to reach an ESWT Tlim outside the desired timeframe of 3–8 minutes [44] and to
decide if ESWT pace should be set a different level than 85% of maximal ISWT pace.
Study limitations
In our design ESWT pace was based on patients’ maximal pace obtained from one ISWT.
Because Dyer et al. reported a learning effect in a second ISWT [45], two ISWT tests are rec-
ommended when the ISWT is used to measure change over time or interventions [19]. How-
ever, when ISWT is only used to set ESWT pace, one test has been postulated to be sufficient
[46]. Although we expect that performing two ISWT’s prior to ESWT might reduce the inter-
individual variability, it does not necessarily eliminate the need of a second ESWT in all
patients. Furthermore, two ISWT’s would increase the amount of tests in all patients, while
our data show that with one ISWT half of the patients perform their ESWT within the desired
duration of 3–8 minutes.
Conclusion
This study confirmed a large interindividual variability in ESWT Tlim in patients with COPD,
as only half of the patients reached an ESWT Tlim within the desired duration of 3–8 minutes.
Our data showed that next to maximal ISWT speed, other ISWT performance measures as
well as clinically available measures of pulmonary function, physical capacity and physical
activity were independent determinants of ESWT Tlim. Nevertheless, these determinants
could only explain ~30% of its variability. Therefore, future studies are needed to establish
whether these and additional factors can be used to better adjust individual ESWT pace in
order to reduce ESWT Tlim variability.
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